Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review_West China Medical Journal

Authors：

Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;

Corresponding author：

Keywords：

硼替佐米; 多发性骨髓瘤; 治疗; 外周血干细胞采集

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的：探讨蛋白酶体抑制剂——硼替佐米对初治多发性骨髓瘤的疗效及对移植造血干细胞采集的影响。方法：对一例初发的中年男性多发性骨髓瘤患者使用硼替佐米+地塞米松+反应停（VTD）的方案进行化疗，获得缓解后采集外周血造血干细胞。结果：应用以硼替佐米为基础的方案治疗3个疗程后，患者即获得完全缓解；完成4个疗程化疗后成功采集足够数量的外周血造血干细胞；完成6个疗程化疗后，进入维持治疗，至今已完全缓解17个月。治疗过程中除恶心、呕吐外无其他明显不良反应。结论：硼替佐米用于初治多发性骨髓瘤有良好的治疗效果，不良反应少，不影响造血干细胞采集。

Citation： LIU Zhigang,NIU Ting,LIU Wei,et al. Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review. West China Medical Journal, 2008, 23(1): 73-74. doi: Copy

1.	[11]Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or High-Dose Dexa methasone for Relapsed Multiple Myeloma[J].N Engl J Med,2005,352:2487-98.
2.	[12]Richardson PG,Chanan-Khan A,Schlossman R,et al.A multicenter phase Ⅱ trial of bortezomib in Patients with previously untreated multiple myeloma:efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy[J].Blood,2005,106:2548.
3.	[13]Wang LM,Weber DM,Delasalle KB,et al.VTD (Velcade,Thelidomide,Dexamethaso me) as primary therapy for newly-diagnosed multiple myeloma[J].Blood,2004,104:210.
4.	[14]Harousseau JL,Attal M,Leleu X,et al.Bortezomib(Velcade)plus decamethas one as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Blood,2004,104:1490.
5.	[15]Peles S,Fisher NM,Devine SM,et al.Bortezomib(velcade)when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)[J].Blood,2005,106:3237.
6.	[16]Geoffrey LU,Fisher NM,Devine SM,et al.Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma[J].Blood,2005,106:2926.
7.	Adams J.The proteasome:structure,function,and role in the cell[J].Cancer Treat Rev,2003,29(suppl 1)3-9.
8.	Kyle RA,Rajkumar SV.Drug therapy of multiple myeloma[J].N Engl J Med,2004,351:1860-73.
9.	Voorhees PM,Dees EC,O’Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:6316-25.
10.	Richardson PG,Mitsiades C.Bortezomib:proteasome inhibition as an effective anticancer therapy[J].Annu Rev Med,2006,57:33-47.
11.	O’Connor OA.Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell ly mphoma[J].Clin Lymphoma Myeloma,2005,6(3):191-9.
12.	Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyelomaactivity of proteasome inhibitor PS-341[J].Blood,2003,101:1530.
13.	Roccaro AM,Hideshima T,Raje N,et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood,2004,104:4903.
14.	Heider U,Kaiser M,Muller C,et al.Treatment of bortezomib increases osteoblast function in patients with multiple myeloma[J].Blood,2005,106:3457.
15.	Richardson PG,Barlogie B,Berenson J,et al.A phase 2study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348:2609-17.
16.	Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progressionin patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-23.

1. [11]Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or High-Dose Dexa methasone for Relapsed Multiple Myeloma[J].N Engl J Med,2005,352:2487-98.
2. [12]Richardson PG,Chanan-Khan A,Schlossman R,et al.A multicenter phase Ⅱ trial of bortezomib in Patients with previously untreated multiple myeloma:efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy[J].Blood,2005,106:2548.
3. [13]Wang LM,Weber DM,Delasalle KB,et al.VTD (Velcade,Thelidomide,Dexamethaso me) as primary therapy for newly-diagnosed multiple myeloma[J].Blood,2004,104:210.
4. [14]Harousseau JL,Attal M,Leleu X,et al.Bortezomib(Velcade)plus decamethas one as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Blood,2004,104:1490.
5. [15]Peles S,Fisher NM,Devine SM,et al.Bortezomib(velcade)when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)[J].Blood,2005,106:3237.
6. [16]Geoffrey LU,Fisher NM,Devine SM,et al.Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma[J].Blood,2005,106:2926.
7. Adams J.The proteasome:structure,function,and role in the cell[J].Cancer Treat Rev,2003,29(suppl 1)3-9.
8. Kyle RA,Rajkumar SV.Drug therapy of multiple myeloma[J].N Engl J Med,2004,351:1860-73.
9. Voorhees PM,Dees EC,O’Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:6316-25.
10. Richardson PG,Mitsiades C.Bortezomib:proteasome inhibition as an effective anticancer therapy[J].Annu Rev Med,2006,57:33-47.
11. O’Connor OA.Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell ly mphoma[J].Clin Lymphoma Myeloma,2005,6(3):191-9.
12. Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyelomaactivity of proteasome inhibitor PS-341[J].Blood,2003,101:1530.
13. Roccaro AM,Hideshima T,Raje N,et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood,2004,104:4903.
14. Heider U,Kaiser M,Muller C,et al.Treatment of bortezomib increases osteoblast function in patients with multiple myeloma[J].Blood,2005,106:3457.
15. Richardson PG,Barlogie B,Berenson J,et al.A phase 2study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348:2609-17.
16. Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progressionin patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-23.

West China Medical Journal

Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review

Abstract Full text Figures/Tables Video References Cited by

Format

Content